290307-39-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclobutoxy-4-difluoromethoxy-benzaldehyde is used as an intermediate for the synthesis of O-Des(Cyclopropylmethyl) O-cyclobutyl Roflumilast (C982940), which is further utilized in the synthesis of Roflumilast (R639700). Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor with significant applications in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
As an intermediate in the synthesis of Roflumilast, 3-Cyclobutoxy-4-difluoromethoxy-benzaldehyde plays a vital role in the development of anti-asthmatic and anti-inflammatory medications. Its unique chemical properties allow for the creation of Roflumilast, which has been proven effective in managing the symptoms of COPD and asthma by reducing inflammation and improving lung function.

Upstream product

• 4399-47-7 Bromocyclobutane 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 499120-83-1 3,5-dichloro-4-(2-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-2-{4-[2,2,2-trifluoro-1-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-phenyl}-ethyl)-pyridine 
• 1026363-26-7 tert-butyl-{4-[chloro-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-methyl]-benzyloxy}-diphenyl-silane 
• 1027864-06-7 3-(6-bromo-pyridin-3-yl)-3-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-2-pyridin-4-yl-propionic acid ethyl ester 
• 552287-72-6 (+/-)-4-{2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[4-(1-carbomethoxy)phenyl]ethyl}pyridine 
• 1026535-58-9 4-[1-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-benzoic acid 
• 552287-71-5 (+/-)-4-{2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[4-(1-hydroxymethyl)phenyl]ethyl}pyridine 
• 290307-28-7 (+/-)-4-{2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-bromo)pyridyl]ethyl}pyridine 
• 290307-29-8 2-bromo-5-[chloro-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-methyl]-pyridine 
• 552287-70-4 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl][4-(1-tert-butyldiphenylsilyloxymethyl)phenyl]methanol 
• 290307-27-6 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-(2-bromopyridin-5-yl)methanol 
• 362719-51-5 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]{2-[(1-trifluoromethyl-1-(2-trimethylsilylethoxy)methoxy)-2,2,2-trifluoro]ethylthiazol-5-yl}methanol 
• 362719-42-4 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]{2-[1-methyl-1-(2-trimethylsilylethoxy)methoxy]ethylthiazol-5-yl}methanol 

Relevant academic research and scientific papers

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: Prevention of reactive intermediate formation and covalent binding

A detailed study directed towards metabolic stability optimization of the alkoxy substituents on the catechol moiety of CDP-840 is reported. Replacement of the methoxy and cyclopentyloxy substituents by cyclobutyloxy and/or difluromethoxy groups resulted in the discovery of potent and selective PDE4 inhibitors where the formation of reactive metabolites that could covalently bind to microsomal protein was significantly reduced or eliminated.